RxDoctor Payments Data

Gary Horwitz, MD

Psychiatry · Pittsford, NYNPI 1598753063

Payments from drug & device makers

$5,656in general payments, 2019–2025

Across 56 payments — averaging $101.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$4K
  • Sunovion Pharmaceuticals Inc.$520
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$400
  • Johnson & Johnson$347
  • Otsuka America Pharmaceutical, Inc.$87
  • Orexo US, Inc.$41
  • plus $27 from 2 others

What the payments were for

  • Speaking & faculty fees$2,95052%
  • Travel & lodging$91616%
  • Food & beverage$1,79032%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,656 in reported general payments places this provider in the 90th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$7,170
Medicare patients
21
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine13$98,256
VraylarCariprazine Hcl11$14,820
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl90$10,532
Paliperidone ErPaliperidone11$2,505
Duloxetine Hcl48$2,351
Buprenorphine Hcl59$2,059
Bupropion XlBupropion Hcl43$1,624
SuboxoneBuprenorphine Hcl/Naloxone Hcl12$1,354
Naltrexone Hcl24$1,136
Clonazepam69$1,005
Venlafaxine Hcl ErVenlafaxine Hcl28$796
Sertraline Hcl43$690
Quetiapine Fumarate23$556
Mirtazapine16$456
Olanzapine28$438

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone$4,234$1,35412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Pittsford

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →